Skip to main content
Top
Published in: Journal of Cancer Survivorship 4/2013

01-12-2013

Perception of body odor—an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer

Authors: D. Alsadius, C. Olsson, N. Pettersson, S. L. Tucker, U. Wilderäng, G. Steineck

Published in: Journal of Cancer Survivorship | Issue 4/2013

Login to get access

Abstract

Purpose

This study was conducted to investigate the association of long-term gastrointestinal and urinary symptoms with perceived fecal or urine body odor after radiation therapy for prostate cancer and its effect on survivors’ quality of life.

Methods

We used a study-specific questionnaire to measure the occurrence of long-term gastrointestinal and urinary symptoms, the perception of fecal or urine body odor, and quality of life (QoL) 2 to 14 years after radiation therapy for prostate cancer. The questionnaire was sent to 895 eligible survivors who assessed symptom occurrence and QoL in the previous 6 months.

Results

We received a filled-in questionnaire from 874 (89 %) men. For the long-term gastrointestinal symptoms, 11/13 were associated with the perception of fecal body odor. For the long-term urinary symptoms, 11/11 were associated with the perception of urine body odor. Men who perceived fecal or urine body odor had a lower quality of life, a lower physical health, and more frequent feelings of depression compared with those who did perceive such body odor.

Conclusion

Long-term gastrointestinal and urinary symptoms after prostate irradiation are associated with the perception of fecal or urine body odor leading to a reduced quality of life.

Implications for cancer survivors

Disabling body odor after pelvic irradiation needs to be acknowledged in the clinic. Interventions to prevent long-term symptoms may serve the benefit of avoiding fecal or urine body odor after radiation therapy for prostate cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–20.PubMedCrossRef Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–20.PubMedCrossRef
2.
go back to reference Gillespie C, Goode C, Hackett C, Andreyev JN. The clinical needs of patients with chronic gastrointestinal symptoms after pelvic radiation therapy. Aliment Pharmacol Ther. 2007;26:555.PubMedCrossRef Gillespie C, Goode C, Hackett C, Andreyev JN. The clinical needs of patients with chronic gastrointestinal symptoms after pelvic radiation therapy. Aliment Pharmacol Ther. 2007;26:555.PubMedCrossRef
3.
go back to reference Andreyev HJN, Vlavianos P, Blake P, Dearnaley D, Norman AN, Tait D. Gastrointestinal symptoms after pelvic radiation therapy: role for the gastroenterologist. Int J Radiat Oncol Biol Phys. 2005;62:1464.PubMedCrossRef Andreyev HJN, Vlavianos P, Blake P, Dearnaley D, Norman AN, Tait D. Gastrointestinal symptoms after pelvic radiation therapy: role for the gastroenterologist. Int J Radiat Oncol Biol Phys. 2005;62:1464.PubMedCrossRef
5.
go back to reference James K. My body produces an offensively pungent chemical. InnovAIT. 2012;5:1. James K. My body produces an offensively pungent chemical. InnovAIT. 2012;5:1.
6.
go back to reference Alsadius D, Hedelin M, Johansson KA, et al. Tobacco smoking and long-lasting symptoms after radiation therapy for prostate cancer. Radiother Oncol. 2111;101:495.CrossRef Alsadius D, Hedelin M, Johansson KA, et al. Tobacco smoking and long-lasting symptoms after radiation therapy for prostate cancer. Radiother Oncol. 2111;101:495.CrossRef
7.
go back to reference Waldenström AC, Olsson C, Wilderäng U, et al. Pain and mean absorbed dose to the pubic bone after radiation therapy among gynecological cancer survivors. Int J Radiat Oncol Biol Phys. 2011;4:1171.CrossRef Waldenström AC, Olsson C, Wilderäng U, et al. Pain and mean absorbed dose to the pubic bone after radiation therapy among gynecological cancer survivors. Int J Radiat Oncol Biol Phys. 2011;4:1171.CrossRef
8.
go back to reference Steineck G, Bergmark K, Henningsohn L, Al-Abany M, Dickman PW, Helgason A. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol. 2002;41:244.PubMedCrossRef Steineck G, Bergmark K, Henningsohn L, Al-Abany M, Dickman PW, Helgason A. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol. 2002;41:244.PubMedCrossRef
9.
go back to reference Steineck G, Helgensen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790.PubMedCrossRef Steineck G, Helgensen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790.PubMedCrossRef
10.
go back to reference Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4. Lancet Oncol. 2011;12:891.PubMedCrossRef Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4. Lancet Oncol. 2011;12:891.PubMedCrossRef
11.
12.
go back to reference Al-Albany M, Helgason AR, Agren Cronqvist AK, et al. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys. 2005;61:1035.CrossRef Al-Albany M, Helgason AR, Agren Cronqvist AK, et al. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys. 2005;61:1035.CrossRef
13.
go back to reference Hopfgarten T, Adolfsson J, Henningsohn L, Onelöv E, Steineck G. The choice between a therapy-induced long-term symptom and shortened survival due to prostate cancer. Eur Urol. 2006;50:280.PubMedCrossRef Hopfgarten T, Adolfsson J, Henningsohn L, Onelöv E, Steineck G. The choice between a therapy-induced long-term symptom and shortened survival due to prostate cancer. Eur Urol. 2006;50:280.PubMedCrossRef
14.
go back to reference Alsadius D, Hedelin M, Lundstedt D, Pettersson N, Wilderäng U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84:e181.PubMedCrossRef Alsadius D, Hedelin M, Lundstedt D, Pettersson N, Wilderäng U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84:e181.PubMedCrossRef
15.
go back to reference Kyrdalen AE, Dahl AA, Hernes E, Småstuen MC, Fosså SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int. 2013;111:221–32.PubMedCrossRef Kyrdalen AE, Dahl AA, Hernes E, Småstuen MC, Fosså SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int. 2013;111:221–32.PubMedCrossRef
16.
go back to reference Harsolia A, Vargas C, Yan D, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiation therapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007;69:1100.PubMedCrossRef Harsolia A, Vargas C, Yan D, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiation therapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys. 2007;69:1100.PubMedCrossRef
17.
go back to reference Pettersson N, Olsson C, Tucker SL, et al. Urethral pain among prostate cancer survivors one to fourteen years after radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:e29.PubMedCrossRef Pettersson N, Olsson C, Tucker SL, et al. Urethral pain among prostate cancer survivors one to fourteen years after radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:e29.PubMedCrossRef
18.
go back to reference van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol. 2006;24:4581.PubMedCrossRef van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol. 2006;24:4581.PubMedCrossRef
19.
go back to reference Janda M, Obermair A, Cella D, Crandon AJ, Trimmel M. Vulvar cancer patients’ quality of life: a qualitative assessment. Int J Gynecol Cancer. 2004;14:875.PubMedCrossRef Janda M, Obermair A, Cella D, Crandon AJ, Trimmel M. Vulvar cancer patients’ quality of life: a qualitative assessment. Int J Gynecol Cancer. 2004;14:875.PubMedCrossRef
20.
go back to reference Steineck G, Hunt H, Adolfsson J. A hierarchical step-model for causation of bias—evaluating cancer treatment with epidemiological methods. Acta Oncol. 2006;45:421.PubMedCrossRef Steineck G, Hunt H, Adolfsson J. A hierarchical step-model for causation of bias—evaluating cancer treatment with epidemiological methods. Acta Oncol. 2006;45:421.PubMedCrossRef
21.
go back to reference Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiation therapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301.PubMedCrossRef Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiation therapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301.PubMedCrossRef
22.
go back to reference Lilleby W, Fosså SD, Wæhre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiation therapy or radical prostatectomy. Int J Radiat Oncol Biol Phys. 1999;43:735.PubMedCrossRef Lilleby W, Fosså SD, Wæhre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiation therapy or radical prostatectomy. Int J Radiat Oncol Biol Phys. 1999;43:735.PubMedCrossRef
Metadata
Title
Perception of body odor—an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer
Authors
D. Alsadius
C. Olsson
N. Pettersson
S. L. Tucker
U. Wilderäng
G. Steineck
Publication date
01-12-2013
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2013
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-013-0304-8

Other articles of this Issue 4/2013

Journal of Cancer Survivorship 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine